key: cord-0904164-u1c3hvbl
authors: Poulin, Marie-France; Pinto, Duane S.
title: Strategies for Successful Catheterization Laboratory Recovery From the COVID-19 Pandemic
date: 2020-06-19
journal: JACC Cardiovasc Interv
DOI: 10.1016/j.jcin.2020.06.032
sha: b862e84853d325e8e6a663606a71092b7bd434a0
doc_id: 904164
cord_uid: u1c3hvbl

ABSTRACT As the world slowly starts to recover from the COVID-19 pandemic, healthcare systems are now thinking about resuming elective cardiovascular procedures, including procedures in the cardiac catheterization laboratories (cath lab). Rebooting cath labs will be an arduous process in part due to limited healthcare resources, new processes and fears stemming from the COVID-19 pandemic. We propose a detailed phased-in approach that considers clinical, patient-centered, and operational strategies to safely and effectively reboot cath lab programs during these unprecedented times. This model balances delivery of essential cardiovascular care while reducing exposure and preserving resources. The guiding principles detailed in this manuscript can be used by cath lab programs when restarting elective interventional procedures.

As the number of new COVID-19 cases stabilizes and some states are lifting stay at home orders, hospitals and physicians are planning to restart non-emergent procedures. However, the COVID-19 pandemic has profoundly affected communities, healthcare professionals and systems in ways that are not yet fully appreciated, creating new challenges when trying to envision a "new normal". Rebooting catheterization laboratories (cath lab) that have been functioning with minimal staffing and altered operations for several weeks poses significant challenges. Here is a perspective on these issues and a proposed strategic plan for a successful cath lab reboot of elective interventional procedures during the recovery from this pandemic.

Factors that must be considered include patient issues, personnel and operational concerns. After months of being told to stay home and avoid hospitals unless absolutely necessary, patients often are fearful of the hospital and reluctant to seek care. Canceled visits, canceled procedures, late presentations and avoidance of care altogether for acute coronary syndrome, stroke, and other acute conditions are evidence for this anxiety (1) (2) (3) . Many have had a change in their health insurance status, with millions losing employment during this crisis. In the coming months, several patients won't be able to take time off for their diagnostic tests and elective procedures due to financial insecurities or fear of losing their current job. Changing patients' perception is likely going to require time and efforts from healthcare systems.

Healthcare facilities in some areas have expanded beyond the limits of normal capacity, and surge areas were created to augment care for patients with COVID-19. Hospitals readiness to resume elective procedures will vary depending on their local current COVID-19 caseload. In some areas, inpatient and intensive care unit (ICU) beds still have significant numbers of COVID-19 patients, also affecting operations for non COVID-19 patients. Often, essential care 4 team members such as physicians, nurses, and technologists have been temporarily reassigned during the crisis and may not be readily available to return to the cath lab. Sadly, some also have been infected with COVID-19 and are still recovering from the disease. Furthermore, personal protective equipment (PPE) remains a limited resource.

Most healthcare systems have reduced the number of diagnostic studies that lead to cath lab referrals including transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), stress testing, and cardiac computed tomography angiography. Referring physicians, both primary care physicians and cardiologists, have also not been seeing these patients in the office due to restrictions in place during the pandemic. While telemedicine has expanded, it is possible that many patients are not seeking care through this alternative pathway. In addition, testing for COVID-19 is not yet readily available everywhere and has diagnostic limitations (see below).

All these factors will impact the rate of cath lab procedures done in the early phase of the reboot.

In order to safely and effectively reboot cath labs, healthcare systems are obligated to comply with federal, state and local public health's recommendations. This mandate includes following guidelines from the Centers for Medicare & Medicaid Services (CMS) which recommends that states pass the "Gating Criteria" prior to restarting non-emergent procedures (4) . This means that states should have a sustained regional reduction in the rate of new COVID-19 diagnosis and cases for at least 14 days, a robust testing program should be in place, and hospitals should have all the required resources to treat non-COVID-19 cases. The latter is dependent upon a healthy workforce across all phases of care, adequate PPE, appropriate number of ICU and non-ICU beds, and required supplies to treat all patients without resorting to a crisis standard of care(4-6).

Guiding principles for a successful pathway to rebooting cath labs are summarized in Figure 1 . Restarting elective cases after the pandemic amplifies and highlights the integrated nature of our healthcare teams. Diligent coordination with other departments is essential to ensure efficiency and success. Specifically, cardiac anesthesia, surgery, environmental services, infection control, facilities, information technology and others must be engaged in developing a coherent and sustainable strategy.

It should be assumed that all emergent cases such as myocardial infarction, shock patients and severe symptomatic valvular heart disease patients in need of urgent treatment are already being treated according to locally established protocols (7, 8) . Waiting patients should be prioritized based on severity of symptoms and other established risk factors. They need to contacted regularly and reclassified as needed while awaiting their procedure. Patients can be classified as Category I (urgent, or at high risk of cardiovascular (CV) complications while waiting), II (semi-urgent, or at moderate CV risk) and III (elective, or at low CV risk) (see Table   1 )(9,10).

Each program needs to implement a model to increase cardiac care in a deliberate and graded fashion with appropriate safeguards and ability to modify in case of a second wave of infection. Recent general guidance has been published on how to reintroduce elective CV care in the pandemic (5, 6) . In addition to these recommendations, we propose the following phased-in model ( Table 2 ). It should be noted that some resource considerations may not apply to regions that have been less affected by the pandemic, but each program can use these guiding principles to tailor their cath lab reboot process. 6 During Phase 1, planned outpatient cases are to be clustered on a few days per week if cath lab staff have not returned from repurposing and ICU beds and holding area hours are still limited. The number of cases scheduled should aim to be ~25% of pre-COVID cath lab volume.

Ideally, the first cases to be scheduled will be Category I patients (Table 1) at risk for adverse cardiac events or urgent hospitalization but also with low risk of intra-procedural complications.

Such a balance may be difficult to strike, but this type of cases would allow for a prompt discharge and minimize the use of hospital resources, especially ICU resources. Organizational strategies including extended hours and performing cases on weekends to decompress weekdays and expedite patient's discharge are available as needed after approbation of the cath lab director. Especially during this Phase, when two therapeutic options such as PCI and CABG are available, additional considerations for the heart team over conventional decision making would be length of stay and ICU bed utilization. As such, the heart team may suggest a minimally invasive procedure (e.g. PCI over CABG) associated with the shorter length of stay and less resource utilization (6) with the understanding that there may be an increased risk for downstream events such as repeat revascularization.

This applies to patients requiring coronary or peripheral revascularization as well as aortic valve replacement.

Assuming a successful implementation of Phase 1 and with the assent of institutional infectious disease experts, Phase 2 can be expected to begin as soon as 1-2 weeks later. Volume of outpatients can be expected to reach ~50% of capacity and few elective cases can be done four days if not all weekdays. Afternoon start times should be avoided to reduce burdens on holding area staff. Flexibility in the schedule and strategies for rapid discharge remain available. Less symptomatic coronary, peripheral and structural patients can be scheduled at that time. Heart 7 biopsies and non-cardiac transplant evaluation can also be scheduled, assuming that transplant programs have also rebooted, and adequate isolation measures for this immunocompromised population are in place to reduce the chances of nosocomial transmission.

Structural and peripheral interventions at low risk to require endotracheal intubation and at low risk for ICU care post-procedure can also be scheduled in Phase 2. This includes patent foramen ovale and atrial septal defect closure that can be performed with intracardiac echocardiography guidance to minimize the risk of aerosolization with TEE. Transcatheter aortic valve replacement (TAVR) without general anesthesia, and peripheral arterial and venous interventions can be considered given the low probability of emergent intubation and cardiopulmonary resuscitation. Other procedural and operational changes to consider adopting for structural heart interventions in the COVID era are listed in Table 3 .

In Phase 3, all elective cases can be scheduled but volume will be at 75% of capacity until resources allow to a transition to Phase 4. Cases can be scheduled any day of the week.

Elective procedure such as stable angina, pulmonary hypertension evaluation, alcohol septal ablation, and CardioMEMS TM implant can be scheduled. Clinical trial enrollment can be expected to resume in Phase 4 when cath labs are functioning normally, albeit with possible reduced efficiency due to new processed in place.

In order to protect and instill confidence amongst healthcare workers and patients, systematic screening for COVID-19 symptoms (cough, fever, new anosmia/ageusia, dyspnea, diarrhea or sore throat) and exposure to known cases should be done for all patients prior to hospital admission (6, 8, 10) . All patients should also get tested with a single swab within 24-48h of their elective procedure and told to self-isolate until their procedure to avoid possible new It should be recognized that no pre-procedure testing strategy can eliminate the possibility of bringing a patient to the hospital in an asymptomatic carrier state. The current false negative rate for COVID-19 PCR-based testing varies from 26%-100% depending on the timing of testing relative to the disease onset (11) . The median false negative rate on the day of exposure is 100%, 39% on the day of symptoms onset and 26% three days later. Factors that can impact clinical sensitivity of nasopharyngeal swab testing include timing of specimen collection relative to the symptoms onset (less sensitive in asymptomatic patients and in more advanced disease) and quality of the sample (11) (12) (13) . Of note, several point-of-care testing kits are also available but are currently not recommended for clinical use by the World Health Organization (14) . In areas where the prevalence of COVID-19 is high, a second test to increase the virus detection may be needed. This decision should be made after conferring with local infectious disease experts. For hospitals without the capacity to perform on-site testing, send-out tests can be done. However, turnover time may be longer creating logistical challenges for scheduling, particularly if testing windows are dogmatic.

Antibody testing are currently under investigation and are not recommended as the sole screening modality pre-procedure. The presence of antibodies confirms a prior infection but may not correlate with immunity. Despite having positive antibodies, some patients still test positive for COVID-19, suggesting that they may still be contagious (15) . Additionally, the absence of antibodies does not exclude an ongoing infection as some patients may not have yet mounted a detectable immune response or may be unable to.

In addition to screening for COVID-19, other important safety measures to reassure patients, healthcare workers and referring physicians should be devised for presumed COVID-19 negative patients presenting for elective procedures. Given the limitations of pre-procedural testing, patients and providers should wear surgical masks at all times. Cath labs should have a dedicated "clean" pathway for elective cases with isolated waiting area, restrooms, preprocedural and recovery areas away from COVID-19 positive patients, as well as dedicated "COVID negative" cath lab room when feasible. Minimizing observation time post-procedure is prudent. A no visitation policy should be enforced in the first Phases of the reboot, and possibly even longer depending on local prevalence of COVID-19. Whenever possible, family's update can be done via video apps to replicate a face-to-face encounter and allow them to see their loved one peri-procedurally. Cath lab teams should avoid congregating in control booths and breakrooms, and assignments should attempt to avoid mixing between COVID positive and COVID negative areas of the cath lab. Daily symptom screening of staff is highly recommended.

Routine COVID testing of the team is controversial and logistically difficult, but can be considered after consultation with local infectious disease experts. The use of telehealth should be maximized for evaluation and follow-up visits of all patients. Recognizing whether a nosocomial infection has occurred is predicated on cath lab staff checking-in with patients after their procedures. If a recrudescence of community COVID-19 or nosocomial infections occur, stopping most elective procedures should occur again until control is reestablished.

The reboot of elective cath lab procedures is expected to be a fluid process during the recovery from this pandemic and differ among regions according to their COVID-19 prevalence.

Close collaboration with national and local health authorities is quintessential to a safe and sustained return to a new normal. The success of cath lab reboots requires complex coordination.

It relies on various programs collaborating to plan and implement standardized, detailed, phasedin approach that incorporates clinical, patient-centered and operational strategies. 

Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong

Collateral damage: medical care avoidance behavior among patients with acute coronary syndrome during the COVID-19 pandemic

Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak

Services CfMM. OPENING UP AMERICA AGAIN Centers for Medicare & Medicaid Services (CMS) Recommendations Re-opening Facilities to Provide Non-emergent Non-COVID-19 Healthcare: Phase I. 2020

Association of periOperative Registered Nurses, and American Hospital Association

Safe Reintroduction of Cardiovascular Services during the COVID-19 Pandemic: Guidance from North American Society Leadership

Clinical Pathway for Management of Suspected or Positive Novel Coronavirus-19 Patients With ST-Segment Elevation Myocardial Infarction

Catheterization Laboratory Considerations During the

COVID 19) Pandemic: A Joint statement from the American College of Cardiology (ACC) Interventional Council and the Society of Cardiovascular Angiography and Intervention (SCAI)

The Restructuring of Structural Heart Disease Practice During The Covid-19 Pandemic

Ramping Up the Delivery of Cardiac Surgery During the COVID-19 Pandemic: A Guidance Statement from the Canadian Society of Cardiac Surgeons

Variation in False Negative Rate of RT-PCR Based SARS-CoV-2 Tests by Time Since Exposure

Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: A narrative review

Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19)

Advice on the use of point-of-care immunodiagnostic tests for COVID-19

The promise and peril of antibody testing for COVID-19